Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy.
Fiche publication
Date publication
juin 2016
Journal
Inflammatory bowel diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Poullenot F, Seksik P, Beaugerie L, Amiot A, Nachury M, Abitbol V, Stefanescu C, Reenaers C, Fumery M, Pelletier AL, Nancey S, Peyrin-Biroulet L, Bourreille A, Hébuterne X, Brixi H, Savoye G, Lourenço N, Altwegg R, Buisson A, Cazelles-Boudier C, Racine A, Vergniol J, Laharie D,
Lien Pubmed
Résumé
Patients with inflammatory bowel disease (IBD) and history of malignancy within the last 5 years are usually contraindicated for receiving anti-tumor necrosis factor (anti-TNF) agents. The aim of this study is to assess survival without incident cancer in a cohort of IBD patients exposed to anti-TNF while having previous malignancy within past 5 years.
Mots clés
Adalimumab, therapeutic use, Adolescent, Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, therapeutic use, Colitis, Ulcerative, complications, Crohn Disease, complications, Disease-Free Survival, Female, Follow-Up Studies, Humans, Incidence, Infliximab, therapeutic use, Male, Middle Aged, Neoplasm Recurrence, Local, epidemiology, Neoplasms, complications, Neoplasms, Second Primary, epidemiology, Survival Rate, Tumor Necrosis Factor-alpha, antagonists & inhibitors, Young Adult
Référence
Inflamm. Bowel Dis.. 2016 06;22(6):1362-9